Search PubMed⌕ Search

Biomedical subjects

F Grignani

Publications and source records attributed to F Grignani.

At least 163 records · Page 9Linked to original sources
PubMed1981

Non-blastic meningeal leukemia during the myelofibrotic phase of chronic myeloid leukemia.

Myeloblastic involvement of the central nervous system has been noted in the course of chronic myeloid leukemia in the blastic phase; meningeal leukemia in the chronic phase of CML is almost unknown. We report on a case of CML in which meningeal infiltration by cells of the granulocytes series in all stage of cellular maturation developed 15 years after initial diagnosis and seven months after a myelofibrotic transformation of the systemic disease.

Adult↗
PubMed1980

Erythrophagocytosis by undifferentiated lung carcinoma cells.

A case is reported of undifferentiated metastatic lung carcinoma in which both a supraclavicular lymph node and bone marrow were infiltrated by anaplastic tumor cells which had engulfed erythrocytes and nucleated elements. The possibility of a histiocytic origin for the phagocytizing neoplastic cells was excluded by ultrastructural, cytochemical, and immunoperoxidase studies. This investigation shows that epithelial tumor cells may, at times develop phagocytizing activity, a phenomenon observed in certain experimentally induced tumors. The mechanism responsible for this phenomenon is not clear.

Bone Marrow↗
PubMed1980

[Bone scintiscanning in the diagnosis and follow-up of breast carcinoma].

Bone scans with Tc + 99m phosphate were performed in 87 patients with histological diagnosis of breast cancer, in order to evaluate whether this technique was suitable in detecting small metastasis both at first staging and in follow-up. The scans were considered as: a) "malignant", when an isotope uptake in usually inactive sites and/or an increased uptake in normally active areas were demonstrated; b) "equivocal", when the uptake in normally inactive and/or in normally active sites was only moderately increased; c) "benign", when only slight uptake increase in normally active structures was detectable. The scans have been carried out before or soon after mastectomy (early scans), and repeated at 6 month intervals (N+ patients and/or malignant or equivocal scans) or at 12 month intervals. A significantly greater incidence of malignant scans was observed in stages 2 and 3 as compared to stage 1, and in stage 4 as compared to all the other stages, as well as in premenopause versus postmenopause patients.

Adult↗
PubMed1979

Combination chemotherapy with 5-fluorouracil and methyl-CCNU for the treatment of advanced gastrointestinal cancer.

Sixteen patients with advanced gastrointestinal cancer (colorectal 12/16, gastric 4/16) were treated with a combination of 5-fluorouracil (5-FU) plus 1-(2-chlorethyl)-3(4-methyl-cycloexyl)-1-nitrosourea (Me-CCNU). The therapeutic program consisted of orally administered Me-CCNU (140 mg/m2) and intravenous 5-FU (9.5 mg/kg by bolus injection for 5 days). The cycles were repeated at 6-week intervals. At the beginning of the therapy, 11/16 patients were in performance status (PS) 0-1 and 5 patients in PS 2-3. Eight patients developed early progressive disease between the 1st and 2nd course of therapy. Only a minor tumor response was observed in the remaining 50% of the patients. However, the patients with stabilized disease lived longer (11.8 months) than non-responders (3.5 months).

Adult↗
PubMed1978

Daunomycin, cytosine arabinoside and 6-thioguanine (DAT) vs vincristine, cytosine arabinoside and 6-thioguanine (VAT) in the induction treatment of acute nonlymphocyte leukemia: a randomized collaborative study.

One hundred patients were entered in a cooperative study comparing the efficacy of two different regimens in the induction treatment of acute nonlymphocytic leukemia (ANLL). Patients were randomly allocated to receive either the DAT or VAT combination; half of the patients were also randomized to receive CNS prophylaxis including intrathecal methotrexate + prednisone and cranial irradiation. Consolidation and maintenance therapy were uniform in responding patients. Out of 82 evaluable patients 41 (50%) attained complete remission (CR) with no significant difference between the two regimens. Median remission duration was slightly longer in the DAT group (32.5 vs 22 weeks); median survival was 34 weeks for all evaluable patients with no difference between the two schedules. Meningeal relapse occurred only in two patients after 19 and 99 weeks of continuous remission. Fourteen patients are still alive after 61 to greater than or equal to 155 weeks, of whom seven are in their initial remission (six in the DAT and one in the VAT group). We conclude that 1) DAT and VAT are equally effective in inducing CR in a high proportion of ANLL patients; 2) until marrow remission can be prolonged significantly, preventing CNS leukemia will not have any significant impact of the course of ANLL.

Adolescent↗